Description
+ Include: 17 videos, size: 1.17 GB
+ Target Audience: hematologists, pathologists, medical oncologists
+ Sample video: contact me for sample video
+ Information:
Target Audience
Learning Objectives
At the conclusion of this activity, participants will be able to:
- Illustrate how cutting-edge data presented at the 2021 Annual Meeting of the American Society of Hematology (ASH) can apply to clinical practice, addressing best practices and guidelines;
- State the emerging treatment strategies for patients with low- and high-risk myeloid malignancies;
- Discuss the optimal patient selection, timing, and regimen for transplant;
- Evaluate clinical trial data in the context of cellular CAR T-cell therapy and its place in evolving hematologic malignancy treatment standards;
- Choose the optimal treatment, sequencing, and supportive care strategies for patients with lymphoma using evidence-based guidelines;
- Identify methods for integrating therapeutic advances such as CAR-T therapies idecabtagene vicleucel (ide-cel) and ciltacabtagene autoleucel (cilta-cel) into practice for myeloma patient care;
- Describe the pathogenesis, diagnostic evaluation and therapeutic modalities available for common benign hematologic diseases and COVID-associated hematologic diseases.
+ Topics:
Advances in Cellular Therapy and Transplantation.ts
ASH Review on Immunotherapies in Leukemia.ts
ASH Review Updates in Nonmalignant Hematology.ts
Myeloma Highlights of ASH 2021.ts
Post-ASH 2021 Cellular Therapy Continuum Initial Consult to Post-Treatment Follow-Up.ts
Post-ASH 2021 Faces of Cellular Therapy Nursing Inpatient Phase.ts
Post-ASH 2021 Nursing Clinical Trials It’s Not Trial By Fire.ts
Post-ASH Case Discussion 59 yo Male With Blurry Vision and Developed Myeloma.ts
Post-ASH Case Discussion 61 yo Female With Progressive Fatigue Who Developed AML.ts
Post-ASH Case Discussion 61 yo Male With Right Neck Swelling Who Developed DLBCL.ts
Post-ASH Case-Based Clinical Trial Considerations Cellular Therapy for Acute Leukemia.ts
Post-ASH Case-Based Clinical Trial Considerations Follicular Lymphoma.ts
Post-ASH Case-Based Review of Multiple Myeloma Clinical Trial Considerations.ts
Post-ASH Evolving Standards of Care in Lymphoma.ts
Post-ASH New Strategies in Myeloid Malignancies AML Treatment.ts
Post-ASH Review Case-Based Clinical Trial Considerations ALL AML.ts
Practice-Changing and Promising New Treatments in Myeloma.ts
Reviews
There are no reviews yet.